Credit Suisse’s Oric Pharmaceuticals ORIC Stock Holding History

Credit Suisse’s Portfolio ORIC Stock Details ORIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-11,300	Closed	-$277K	–	4568
2021 Q1	$277K	Buy	+11,300	New	+$357K	﹤0.01%	4023

Other funds holding ORIC

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Column Group San Francisco, California $88.1M AUM 148.03% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Credit Suisse's ORIC Position: Q3 2022 in Review

Credit Suisse sold out of Oric Pharmaceuticals (ORIC) in Q3 2022, closing a stake of 17 shares.

Credit Suisse first reported a position in ORIC in Q4 2020 and held it in 7 quarters. The position peaked at $722K in Q4 2020. 76 funds tracked by Wall St. Rank hold ORIC as of Q3 2022.

Credit Suisse reported no remaining Oric Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
Credit Suisse sold 17 Oric Pharmaceuticals shares in Q3 2022.
Credit Suisse first reported a position in Oric Pharmaceuticals in Q4 2020 and held it in 7 quarters.
Credit Suisse's Oric Pharmaceuticals position peaked at $722K in Q4 2020.
76 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q3 2022.

Based on Credit Suisse's 13F filing for Q3 2022, filed 10 Nov 2022.